[{"id":"84233739-ed53-4cf9-9895-5c8bd3e952d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03043391","created_at":"2021-01-18T14:59:13.296Z","updated_at":"2024-07-02T16:35:10.938Z","phase":"Phase 1","brief_title":"Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children","source_id_and_acronym":"NCT03043391","lead_sponsor":"Istari Oncology, Inc.","biomarkers":" NF1","pipe":" | ","alterations":" NF1 mutation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lerapolturev (PVS-RIPO)"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 11/07/2017","start_date":" 11/07/2017","primary_txt":" Primary completion: 03/23/2022","primary_completion_date":" 03/23/2022","study_txt":" Completion: 03/23/2022","study_completion_date":" 03/23/2022","last_update_posted":"2024-04-08"},{"id":"2f59a817-0e8b-44c9-812f-3c051a1229d1","acronym":"LUMINOS-102","url":"https://clinicaltrials.gov/study/NCT04577807","created_at":"2021-01-18T21:51:05.215Z","updated_at":"2024-07-02T16:35:11.133Z","phase":"Phase 2","brief_title":"LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma","source_id_and_acronym":"NCT04577807 - LUMINOS-102","lead_sponsor":"Istari Oncology, Inc.","biomarkers":" PD-L1 • BRAF • CD8","pipe":" | ","alterations":" PD-L1 expression • BRAF mutation • BRAF wild-type","tags":["PD-L1 • BRAF • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF mutation • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lerapolturev (PVS-RIPO)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 11/17/2020","start_date":" 11/17/2020","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2024-04-05"},{"id":"c55d98dc-4757-49c8-ba40-0336728471cd","acronym":"","url":"https://clinicaltrials.gov/study/NCT03564782","created_at":"2021-01-18T17:33:07.799Z","updated_at":"2024-07-02T16:35:20.243Z","phase":"Phase 1","brief_title":"Examining Bioactivity of PVSRIPO in Invasive Breast Cancer","source_id_and_acronym":"NCT03564782","lead_sponsor":"Istari Oncology, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative • HER-2 expression • ER expression • PGR expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative • HER-2 expression • ER expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lerapolturev (PVS-RIPO)"],"overall_status":"Completed","enrollment":" Enrollment 5","initiation":"Initiation: 06/30/2019","start_date":" 06/30/2019","primary_txt":" Primary completion: 04/11/2022","primary_completion_date":" 04/11/2022","study_txt":" Completion: 04/11/2022","study_completion_date":" 04/11/2022","last_update_posted":"2024-02-08"},{"id":"800689f3-ecd9-4222-8b49-07a4c0b8d155","acronym":"","url":"https://clinicaltrials.gov/study/NCT03712358","created_at":"2021-01-18T18:11:54.177Z","updated_at":"2024-07-02T16:36:07.959Z","phase":"Phase 1","brief_title":"PVSRIPO for Patients With Unresectable Melanoma","source_id_and_acronym":"NCT03712358","lead_sponsor":"Istari Oncology, Inc.","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lerapolturev (PVS-RIPO)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 11/26/2018","start_date":" 11/26/2018","primary_txt":" Primary completion: 03/23/2021","primary_completion_date":" 03/23/2021","study_txt":" Completion: 03/23/2021","study_completion_date":" 03/23/2021","last_update_posted":"2022-06-30"},{"id":"b3f4a94b-bcac-4ec0-a7ee-4fe5496dbffc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04125719","created_at":"2021-01-18T20:09:23.257Z","updated_at":"2025-02-25T14:28:47.553Z","phase":"Phase 1","brief_title":"PVSRIPO in Combination With Nivolumab in Melanoma","source_id_and_acronym":"NCT04125719","lead_sponsor":"Darell Bigner","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • lerapolturev (PVS-RIPO)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/01/2020","start_date":" 06/01/2020","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2020-02-11"}]